IOVANCE BIOTHERAPEUTICS, INC.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA): 15 pipeline candidates · 3 upcoming catalysts · ~15 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.9 months
D/E 0.28 · 0% dilution
Lead: Approved
15 candidates
3 upcoming, next in ~1352d
N/A
A transparent, data-derived signal for IOVANCE BIOTHERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$202.5M
Quarterly Burn
$72.1M
Runway
14.9 mo
Revenue
$71.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (15 candidates)
| Drug | Phase |
|---|---|
| amtagvi | Approved |
| High dose IL-2 | Phase 1 |
| IL-2 | Phase 1 |
| IOV-2001 | Phase 1 |
| IOV-3001 | Phase 1/Phase 2 |
| iov-4001 | Phase 1/Phase 2 |
| iov-5001 | Phase 1/Phase 2 |
| Lifileucel | Phase 2 |
| ln-145 | Phase 1 |
| LN-145 | Phase 2 |
Showing 10 of 15 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
287
Total value held
$996.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 33,235,474 | $116.7M |
| blackrock, inc. | 31,080,505 | $109.1M |
| mhr fund management llc | 28,967,103 | $101.7M |
| state street corp | 17,448,108 | $61.2M |
| two sigma investments, lp | 13,687,433 | $48.0M |
| vanguard portfolio management llc | 11,700,844 | $41.1M |
| millennium management llc | 9,414,292 | $33.0M |
| goldman sachs group inc | 8,760,060 | $30.7M |
| geode capital management, llc | 8,572,598 | $30.1M |
| invenomic capital management lp | 8,495,551 | $29.8M |
Showing top 10 of 287 institutional holders of IOVANCE BIOTHERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in IOVANCE BIOTHERAPEUTICS, INC.'s pipeline?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has 15 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IOVANCE BIOTHERAPEUTICS, INC.'s lead drug candidate?
IOVANCE BIOTHERAPEUTICS, INC.'s most advanced tracked candidate is amtagvi (Approved) for Unresectable Melanoma.
What is IOVANCE BIOTHERAPEUTICS, INC.'s next catalyst?
IOVANCE BIOTHERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Effica" — expected March 1, 2030.
What is IOVANCE BIOTHERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IOVANCE BIOTHERAPEUTICS, INC. has approximately 14.9 months of cash runway.
What is IOVANCE BIOTHERAPEUTICS, INC.'s market capitalization?
IOVANCE BIOTHERAPEUTICS, INC.'s market capitalization is approximately $1.8B.
Get the full picture on IOVANCE BIOTHERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.